Navigation Links
Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering
Date:1/3/2011

HONG KONG, Jan. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech Holdings Limited ("Golden Meditech" or the "Company," together with its subsidiary collectively as the "Group" - 801.HK), Mainland China's leading integrated healthcare enterprise, is pleased to announce that the Company has obtained the approvals from the Taiwan Stock Exchange and the Taiwan Securities and Futures Bureau for its proposed offering and listing of Taiwan Depositary Receipts ("TDR") on the Taiwan Stock Exchange.  The Company will become the first Mainland Chinese healthcare enterprise to list its TDR on the Taiwan Stock Exchange.

The Company intends to offer 90 million TDR units (equivalent to 180 million ordinary Shares of the Company).  A portion of the proceeds will fund the establishment of a representative office in Taiwan.  In view of the rare opportunities arising from the Economic Cooperation Framework Agreement ("ECFA") so as to foster closer ties between industry counterparts on both sides of the Taiwan Strait, the Company is actively pursuing to strengthen its core businesses and market presence through Taiwan's talent advantage.  

According to the Company's recently published interim results in accordance with Hong Kong Accounting Standards, the Group's revenue for the six month ended September 30th, 2010 amounted to HK$163 million with 24% growth relative to the previous corresponding period.  Profit for the period amounted to HK$161 million with 170% growth relative to the previous interim reporting period.

Mr. Kam Yuen, the Company's Chairman and Chief Executive Officer pointed out that the rapid growth of the Group's hospital management business, the penetration of the Autologous Blood Recovery Systems into mid-tier hospitals and the substantial growth in medical accessories consumption all contributed to the increase in the Group's revenue for the period.  The hospital management business accounted for 23% of the Group's total revenue at HK$38million.

About Golden Meditech Holdings Limited

Golden Meditech Holdings Limited is China's leading integrated-healthcare device and service operator, and the first medical device enterprise that was publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx).  Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets over the years, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities.  Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.

For enquiries, please contact:

Investor Relations Department

Golden Meditech Holdings Limited

Address:

48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong

Tel: +852-3605-8180

Fax: +852-3605-8181

Email: ir@goldenmeditech.com

Website: www.goldenmeditech.com


'/>"/>
SOURCE Golding Meditech Holdings Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Golden Meditech Announces Annual Results for FY 2009/10
2. Golden Meditech Announces Plan to Issue Taiwan Depository Receipts
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
5. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... On Thursday, February 16, 2017, ... at the closing bell, while the Dow Jones Industrial ... Moreover, five out of nine sectors ended Thursday,s trading ... sentiment, Stock-Callers.com assessed the following Medical Appliances & Equipment ... SNN ), ABIOMED Inc. (NASDAQ: ABMD ...
(Date:2/16/2017)... 16, 2017 DaVita Inc. (NYSE: DVA ... December 31, 2016. Net income attributable to ... 2016 was $158 million, or $0.80 per share and $880 ... net income attributable to DaVita Inc. for the quarter and ... below, was $192 million, or $0.98 per share, and $789 ...
(Date:2/16/2017)...  Express Scripts (NASDAQ: ESRX ) was recognized today ... within the Health Care: Pharmacy and Other Services category. ... Most Admired Companies," said Tim Wentworth , CEO and President, ... of our 26,000 employees to make medicine more affordable and accessible ... ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each ... goals for each and every seminar, session and class she offers. ... different brainwave tools which help energize creativity, focus mental functions, enhance athletic focus ...
(Date:2/17/2017)... ... 2017 , ... Qualis Health, one of the nation's leading ... DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that are ... award categories, highlighting four of the organization’s current programs:, , ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... fall 2017 season , Trinity Health and the U.S. Soccer Foundation announced today ... program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... – 22 in San Francisco. As part of the Tri-Conference expo, which is ... solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , ...
Breaking Medicine News(10 mins):